Thatcher N, Dazzi H, Johnson R J, Russell S, Ghosh A K, Moore M, Chadwick G, Craig R D
Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, UK.
Br J Cancer. 1989 Nov;60(5):770-4. doi: 10.1038/bjc.1989.357.
Recombinant interleukin-2 (rIL-2) was used to treat 31 patients with progressing metastatic malignant melanoma. Only three patients had disease confined to non-visceral sites; the median number of organ sites involved was four. The first dose of rIL-2 was given intrasplenically (to stimulate cytotoxic cells in high concentration) via a femoral artery catheter, and four further i.v. doses were given over 6 days. A total of three courses at 21-day intervals was planned. Doses were escalated in 15 patients from 1 x 10(6) to 16.4 x 10(4) Cetus units m-2. The maximum tolerated dose (11.0 x 10(6) U m-2) was used in the other 16 patients. Of the 71 courses, severe but transient toxicity requiring interruption of rIL-2 or additional care occurred on three courses (dyspnoea) and 15 from hypotension, but the patients' performance status improved. Four patients had partial tumour responses although in only one patient did response occur in all sites of disease. However, responses occurred in visceral sites and six patients are alive at 9-16 months. IL-2 is of use in advanced melanoma and does not need complicated ICU facilities.
重组白细胞介素-2（rIL-2）被用于治疗31例进展期转移性恶性黑色素瘤患者。仅有3例患者的疾病局限于非内脏部位；累及器官部位的中位数为4个。rIL-2的首剂通过股动脉导管经脾内给药（以高浓度刺激细胞毒性细胞），并在6天内静脉注射另外4剂。计划每21天进行总共3个疗程。15例患者的剂量从1×10⁶增至16.4×10⁴Cetus单位/平方米。另外16例患者使用最大耐受剂量（11.0×10⁶U/平方米）。在71个疗程中，有3个疗程出现严重但短暂的毒性反应，需要中断rIL-2治疗或增加护理（呼吸困难），15个疗程出现低血压，但患者的体能状态有所改善。4例患者出现部分肿瘤反应，尽管仅1例患者在所有疾病部位均出现反应。然而，内脏部位出现了反应，6例患者在9至16个月时仍存活。IL-2对晚期黑色素瘤有用，且不需要复杂的重症监护设施。
